Abstract | PURPOSE: PATIENTS AND METHODS: Eighty-six stage 4 neuroblastoma patients older than 1 year at diagnosis were classified in four clinical groups on protocol entry: complete remission or very good partial remission (n = 33), primary refractory (n = 33), secondary refractory (n = 10), and progressive disease (n = 10). Bone marrow samples collected before and following treatment were assayed for GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction. Response and survival analyses were performed on posttreatment samples before the third cycle at 1.8 months from protocol entry. RESULTS:
GD2 synthase mRNA was evident in pretreatment marrow samples of the four clinical groups (42%, 52%, 60%, and 80% of samples, respectively), with median transcript level of 10.0, 16.6, 26.5, and 87.2, respectively. This marker became negative following antibody plus GM-CSF in 77% of complete remission or very good partial remission, 45% of primary refractory, 25% of secondary refractory, and 0% of progressive disease group. Progression-free survival was statistically different between responder and nonresponder groups (P <.0001). Among patients with minimal residual disease, molecular responders had a significantly lower risk of disease progression at a median follow-up of 29.8 months (P =.0001). CONCLUSION:
|
Authors | Irene Y Cheung, M Serena Lo Piccolo, Brian H Kushner, Nai-Kong V Cheung |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 21
Issue 20
Pg. 3853-8
(Oct 15 2003)
ISSN: 0732-183X [Print] United States |
PMID | 14551304
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- 3F8 antibody
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Biomarkers, Tumor
- Immunoglobulin G
- RNA, Messenger
- Recombinant Proteins
- Granulocyte-Macrophage Colony-Stimulating Factor
- N-Acetylgalactosaminyltransferases
- (N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- Biomarkers, Tumor
(analysis)
- Bone Marrow
(enzymology)
- Bone Marrow Neoplasms
(therapy)
- Granulocyte-Macrophage Colony-Stimulating Factor
(therapeutic use)
- Humans
- Immunoglobulin G
(therapeutic use)
- Infant
- N-Acetylgalactosaminyltransferases
(analysis)
- Neoplasm, Residual
- Neuroblastoma
(therapy)
- Prognosis
- RNA, Messenger
(analysis)
- Recombinant Proteins
(therapeutic use)
|